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7INTRODUCTION
Infection with Human immunodeficiency virus (HIV) and its end stage 
Acquired immunodeficiency syndrome (AIDS) is the major public challenge of 
modern times, with over 25 million persons already dead and over 30 million 
living with HIV / AIDS, the majority of whom are without access to therapy58.
Opportunistic  infection  continue  to  cause  morbidity  and  mortality  in 
patients with human immunodeficiency virus infection throughout the world66.
Although the incidences of opportunistic infections have been reduced 
around  the  globe  by  Highly  Active  Anti  Retroviral  Therapy(HAART),  the 
situation remains the same in most developing countries including India52. This 
is due to the fact that some patients do not have access to the treatment and 
others  do  not  have  sustained  response  to  antiretroviral  drugs  for  multiple 
reasons including poor adherence, drug toxicities, drug interactions or initial 
acquisition of a drug resistant strains66.
Oropharyngeal candidiasis is the most common opportunistic infection 
observed  in  AIDS  patients,  occurring  in  an  estimated  80  to  95%  of  these 
patients  when  the  CD4  T  lymphocyte  counts  are  below  200  cells  /mm3 
.Increased retroviral replication and an associated decline in immune defenses 
render  these  patients  more  susceptible  to  oropharyngeal  candidiasis23,26,13. 
Presenting  months  or  years  before  more  severe  opportunistic  infection, 
oropharyngeal candidiasis may be a sentinel event indicating the presence or 
progression  of  HIV  disease.  Although  usually  not  associated  with  severe 
morbidity,  oropharyngeal  candidiasis  can  be  clinically  significant.  Severe 
8oropharyngeal candidiasis can interfere with the administration of medication 
and adequate nutritional intake33.
The prolonged nature of AIDS predisposes these patients to recurrent 
episodes  of  oropharyngeal  candidiasis  that  can  increase  in  frequency  and 
severity with progressive HIV disease.Therfore the prolonged management of 
Oropharyngeal Candidiasis in these patient population causes the development 
of drug resistant candidiasis3,79.
Antifungal  drug  resistance  is  fast  becoming  a  major  problem12,41. 
Fluconazole has been successful in  treating Oropharyngeal Candidiasis in HIV 
infected patients  but its  long term use and increased immunosuppression in 
HIV  patients  as  assessed  by  the  CD4  count  raises  the  possibility  of  the 
acquisition of  resistance by the yeast Candida albicans45,68. Many studies have 
estimated the incidence of clinical fluconazole resistance to be around 5-10%63. 
The  increased  reports  of  antifungal  resistance  and  expanding  drug  therapy 
options  prompted  the  need  for  clinically  relevant  antifungal  susceptibility 
testing.  Further  the  emergence  of  other  Candida  species such  as  Candida 
krusei and  Candida  glabrata with  innately  reduced  susceptibilities  to 
fluconazole22 also  results  in  treatment  failure,  emphasizing  the  need  for 
speciation  of the oral yeast isolates.
Considering the above the facts,  the present study was conducted  to 
determine the species distribution and antifungal susceptibility profiles of the 
Candida isolates from HIV patients with Oropharyngeal Candidiasis.
9REVIEW OF LITERATURE
HUMAN IMMUNODEFICIENCY VIRUS
        AIDS was first recognised in the summer of 1981, when the US centres 
of  disease  control  and  prevention  reported  the  unexplained  occurrence  of 
Pneumocystis   jirovecii among  homosexual  men  in  Los  Angeles  and  an 
outbreak of a rare form of cancer among gay men in Newyork and California , 
medically  known  as  Kaposi  sarcoma.  Within  months  ,  the  disease  became 
recognised  in  male  and  female  injection  drug  users  and  soon  thereafter  in 
recipients  of  blood transfusions  and in  hemophiliacs.  As  the  epidemiologic 
pattern of the disease unfolded, it became clear that a microbe transmissible by 
sexual contact and blood or blood products or from mother to infants was the 
most likely etiologic agent.
 In  1983,  Luc  Montagnier  isolated  the  virus  from  a  patient  with 
lymphadenopathy and by 1984 it was demonstrated clearly to be the causative 
agent of AIDS. In 1985, a sensitive enzyme linked immunosorbent assay was 
developed37.
           The etiologic agent of AIDS is HIV, which belongs to the family of 
human retroviruses and the subfamily of lentiviruses. There are two distinct 
types  of  human AIDS viruses  namely  HIV-1 and HIV-2.The  two types  are 
distinguished  on  the  basis  of  genome  organization  and  phylogenetic 
relationship with other primate lentiviruses43.
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The most common cause of HIV disease throughout the world is HIV-1. 
HIV-2 was first identified in 1986 in West African patients and was originally 
confined  to  West  Africa.  However  a  number  of  cases  have  been  identified 
throughout the world37.
           HIV-1 is subdivided into three genetic groups designated M (Major), O 
(Outlier) and N (Non- M, Non – O) based on sequence diversity within the 
HIV –I gag and env genes.HIV-1 group is divided into 9 subtypes(A-D,F-H, 
J&K)10.Subtypes differ in mode of transmission, geographical distribution and 
biologic characteristics. Subtype C viruses are the most common worldwide. 
The predominant subtype in Europe and the America is Subtype B. Subtype C 
is prevalent in India70.
HIV-1  and  HIV-2  have  the  same  mode  of  transmission.  The  most 
common mode of HIV infection is sexual transmission – both homosexual and 
heterosexual contact. Infection may also occur through inoculation of infected 
blood products, via transfusion of infected blood products, transplantation of 
infected  tissues  or  through  contaminated  needle10.Large  multi  institutional 
studies have indicated the risk of transmission  following skin puncture with 
needle contaminated with blood from a HIV infected person as 0.3% and after 
mucous  exposure  it  is  0.09%.The  other  mode  of  transmission  is  from  the 
infected mother to the child either intrapartum, perinatally or via breast milk37.
The hallmark of HIV disease is a profound immunodeficiency resulting 
primarily  from  a  progressive  quantitative  and  qualitative  deficiency  of  the 
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subset of T lymphocytes referred to as helper T cells or inducer T cells. This 
subset of T cells is defined phenotypically by the presence on its surface of the 
CD4 molecule  which  serve  as  the  primary  receptor  for  HIV.HIV uses  two 
major coreceptors namely CCR5 and CXCR4 for fusion and entry37.
 After attachment, HIV RNA and enzymes are released into the host cell. 
Viral replication requires that reverse transcriptase (an RNA-dependent DNA 
polymerase)  copy  HIV  RNA,  producing  proviral  DNA;  this  copying 
mechanism is prone to errors, resulting in frequent mutations. These mutations 
facilitate the generation of HIV that can resist control by the host's immune 
system and by antiretroviral drugs. Proviral DNA enters the host cell's nucleus 
and is integrated into the host DNA in a process that involves HIV integrase. 
With each cell division, the integrated proviral DNA is duplicated along with 
the host DNA. Proviral HIV DNA is transcribed to viral RNA and translated to 
HIV proteins,  including  the  envelope  glycoproteins  40  and  120.  The  HIV 
proteins are assembled into HIV virions at the inner cell membrane and budded 
from the cell surface; each host cell may produce thousands of virions. After 
budding, protease, another HIV enzyme, cleaves viral proteins, converting the 
immature virion into a mature, infectious form .
 The main consequence of HIV infection is damage to the immune system, 
specifically loss of  CD4+ lymphocytes,  which are involved in cell-mediated 
and, to a lesser extent,  humoral immunity. CD4+ lymphocyte depletion may 
result from the following:
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• Direct cytotoxic effects of HIV replication
• Cell-mediated immune cytotoxicity
• Thymic damage that impairs lymphocyte production
 Infected CD4+ lymphocytes have a half-life of about 2 days, which is 
much shorter than that of uninfected CD4+ cells. Rates of CD4+ lymphocyte 
destruction correlate  with plasma HIV level.  Typically,  during  the  initial  or 
primary infection, HIV levels are highest (>106 copies/mL), and the CD4 count 
drops  rapidly.  The  normal  CD4  count  is  about  750/μL,  and  immunity  is 
minimally affected if the count is > 350/μL. If  the count drops below about 
200/μL, a variety of opportunistic pathogens may produce clinical disease. The 
humoral immune system is also affected 2.
LABORATORY INVESTIGATIONS FOR HIV INFECTION
(i) Laboratory methods for the diagnosis of HIV infection
(ii) Laboratory  methods  for  monitoring  Stage  and  Progression  of 
Infection70  .
(i)Laboratory methods for the diagnosis of HIV infection
(I) Indirect Methods (Antibody detection methods)
(ii)Direct Methods
DETECTION OF SPECIFIC ANTIBODIES
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Detection of anti –HIV antibodies is the main stay of diagnosing HIV.
Tests to detect specific antibodies can be classified into
• Screening tests
o Conventional ELISA
o Rapid tests
Rapid  tests  are  in  vitro  qualitative  tests  for  the  detection  of 
antibodies to   HIV-1 and HIV-2 in serum, plasma, whole blood , saliva 
and urine.
-Immunoconcentration (Dot blot assays)
-Particle agglutination
-Immunochromatography(lateral flow)
-Immunocomb(Dipstick/comb tests)
• Supplemental tests(Confirmatory tests)
-Western Blot
-Immunoblot
-Lineimmuno assay
-Indirect fluorescent antibody test
-Radioimmunoprecipitation tests69
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DIRECT DETECTION OF HIV INFECTION
HIV infection is diagnosed mainly by detecting the HIV antibodies. But 
there are situations where the serology is negative although there is definite 
evidence of exposure to HIV infection. Direct Detection methods are needed in 
the following settings
(i) To determine HIV status during the window period 
(ii) In  health  care  workers  following  accidental  exposure  to 
contaminated blood. 
(iii) Also children born to HIV infected mother present dilemma as 
antibody positivity seen upto 18 months may be due to maternal 
antibodies. 
The diagnosis in such situation can be made by direct detection method like
• Detection of p24 antigen
• Detection of HIV specific DNA                      
• Isolation of Virus by culture
(ii)Laboratory tests for monitoring stage and progession of HIV Infection
They are classified into
Viral markers                                   Immunologic markers
Plasma HIV RNA load                                 CD4 count
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P24 antigenemia
Viral specific markers like antibodies to HIV antigens(p24, p17,nef) and 
soluble  markers  of  immune  activation  like  neopterin  ,  β2  microglobulin 
previously recommended for monitoring the course of HIV infection are no 
longer recommended.
The close relationship between clinical manifestations of HIV infection 
and CD4+ T cell count has made measurements of the CD4 count as a routine 
part of the evaluation of HIV infected individuals70.
CD4 T cell counts
The progressive depletion of CD4+ T lymphocytes is the cardinal event 
in the pathogenesis of infection by the human immunodeficiency virus.  The 
number  of  these  cells  in  the  peripheral  blood  is  the  single  most  important 
parameter for monitoring the disease associated with HIV infection.
Determinants of CD4+ T cell counts and measurements of the HIV-RNA 
levels in serum or plasma provides a powerful tools for determining prognosis 
and monitoring response to therapy37.
 Throughout  the course  of  the  disease,  the total  T cell  levels  remain 
fairly constant despite a fall in CD4 T lymphocyte count, due to a concomitant 
rise in CD8 T lymphocytes .Therefore, the ratio of CD4 T lymphocytes to CD8 
T  lymphocytes  is  an  additional  important  measure  of  disease  progression. 
Measurement of lymphocyte subsets is done by flow cytometry which is the 
gold standard for enumeration of CD4 T lymphocytes. 
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CD4 T lymphocytes enumeration is also utilized as a surrogate marker 
for HIV-induced damage .The declining slope of CD4 T lymphocytes counts, 
indicates  the  speed  of  progression  towards  AIDS.  While  on  therapy, 
improvement  in  CD4 T lymphocytes  counts  is  indicative  of  the  success  of 
therapy. In resource-poor countries, with the arrival of generic drugs for anti-
retroviral therapy, the need for CD4 T lymphocytes counts has dramatically 
increased. CD4 T lymphocytes counts are the criteria for initiating ART as well 
as monitoring the therapeutic response in a patient16.
Flow Cytometry: 
          Flow cytometry uses the principles of light scattering , light 
excitation, and emission of fluorochrome molecules to generate specific 
multi-parameter  data  from  particles  .The  cellular  suspension  is 
incubated  previously  with  monoclonal  antibodies  conjugated  with 
different fluorochromes  and it is introduced in the hydraulic system so 
that  the  cells  pass  individually  through the flow chamber,  where  the 
laser beam intercepts the cells. These contact produces two different 
dispersion patterns : the frontal dispersion (Forward Scatter, A) gives us 
information  about  the  cellular size ,  while  lateral  dispersion  (Side 
Scatter,  B)  informs  us  about cellular  complexity.  The  monoclonal 
antibodies linked to cellular surface is at the same time excited by the 
laser and generate fluorescences that are collected by photomultipliers 
(up to 4 at the moment) that transform the optic to electric signal, then 
cytometer send all information to the computer system for later analysis.
(FACS facility)
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Fluorescence-activated cell sorting is a specialized type of flow 
cytometry. It provides a method for sorting a heterogeneous mixture of 
biological  cells into two or more containers, one cell at a time, based 
upon the specific light scattering  and fluorescent characteristics of each 
cell.  It  provides  quantitative  recording  of  fluorescent  signals  from 
individual cells as well as physical separation of cells of interest40.  
CD4 cell count is extremely important in the staging of HIV infection 
and revised classification of the Center of Disease Control divides HIV positive 
patients into three categories.
CDC CLASSIFICATION SYTEM OF HIV INFECTION
CD4+ T-cell 
count (cells/µl.) 
(CD4%)
Asymptomatic, acute 
(primary) HIV or 
PGL
Symptomatic, not A 
or C conditions
AIDS-indicator 
conditions
> 500 (28%) A1 B1 C1
200–499 (15–
28%)
A2 B2 C2
< 200 (14%) A3 B3 C3
Category  A:  asymptomatic  HIV  infection,  persistent  generalized 
lymphadenopathy (PGL).
Category  B:  oropharyngeal  and  vulvovaginal  candidiasis,  constitutional 
symptoms such as fever (38·5°C) or diarrhea lasting >1 month, herpes zoster 
(shingles).
Category  C: Mycobacterium  tuberculosis (pulmonary  and  disseminated),  
Pneumocystis   carinii pneumonia,  candidiasis  of  bronchi;  trachea  or  lungs, 
extrapulmonary  cryptococcosis,  CMV,  HIV-related  encephalopathy,  Kaposi's 
sarcoma, wasting syndrome due to HIV.
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 When the number of CD4+ T cells declines below a certain level , the 
patient  is  at  high  risk  of  developing  a  variety  of  opportunistic  diseases, 
particularly the infections and neoplasms that are AIDS defining illness37.
Opportunistic infections in HIV patients
Bacterial Infections
• Bacterial Diarrhea
• Bacterial Pneumonia
• Mycobacterium Avium Complex (MAC)
• Mycobacterium Kansasii
• Syphilis & Neurosyphilis
• Tuberculosis 
Malignancies (Cancers)
• Anal Dysplasia/Cancer
• Cervical Dysplasia/Cancer
• Kaposi's Sarcoma, Lymphomas
Viral Infections
• Cytomegalovirus (CMV)
• Hepatitis C
• Herpes  Simplex  Virus  (oral  &  genital 
herpes)
• Herpes Zoster Virus (shingles)
• Human  Papilloma  Virus  (HPV,  genital 
warts, anal/cervical dysplasia/cancer)
• Molluscum Contagiosum
• Oral Hairy Leukoplakia (OHL)
• Progressive  Multifocal 
Leukoencephalopathy72 
Fungal Infections
• Candidiasis 
• Aspergillosis
• Coccidioidomycosis
• Cryptococcal Meningitis
• Histoplasmosis
Protozoal Infections
• Cryptosporidiosis
• Isosporiasis
• Microsporidiosis
• Toxoplasmosis
Neurological Conditions
• AIDS  Dementia 
Complex79 
• Peripheral Neuropathy
Others
• Aphthous Ulcers
• Thrombocytopenia 
• Wasting Syndrome
The first overt indication of AIDS may be opportunistic infection with 
the fungus Candida albicans, which causes appearances of sores in the mouth 
(Thrush)49.
CANDIDA
History
Oral candidiasis has been recognised as a clinical entity since the time of 
Hippocrates  in  his  “Epidemics”  described  aphthae  or  thrush  in  debilitated 
patients84. The first binomial to gain wide acceptance  was  Monilia albicans 
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which was suggested by Zopf in 1890. Berkhout in 1923, after recognising the 
difference between  Monilia sp  isolated from rotting plants and those isolated 
from medical cases established the genus Candida to accommodate the later77. 
This  was accepted as the official  name of the genus by the Eight botanical 
congress in Paris in 1954.
Two major medical events have revived the interest in fungal diseases in 
general and Candida infections in particular .
The first was the introduction of antibacterial drugs in the second half of 
the  twentieth  century.  These  drugs   may  act  as  a  predisposing  factor  for 
mycotic infections causing an imbalance of host’s natural  microbial  flora in 
favour of fungi, upon which they have inhibitory activity .The second event 
was the increase in the prevalence of immunosuppressed patients during the 
last few decades, as a result of chemotherapy or disease [AIDS], which led to a 
parallel increase in the incidence of Candida infections in general and the less 
pathogenic non- albicans Candida species in particular94.
Taxonomy
The  Genus Candida belongs  to  the  phylum  Ascomycota,  in  class 
Ascomycetes , in order Saccharomycetales and family Saccharomycetaceae94,9.
       Genus  Candida includes  more  than  150  species.  Frequent  human 
pathogens are83
Candida albicans (Robin) Berkhout 1923
Synonymy : Oidium albicans /   Monilia albicans
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Candida  guilliermondii (castellani)1938  (Teleomorph  :  Pichia 
guilliermondii)50
Synonymy : Endomyces guilliermondii/  Monilia guilliermondii
Candida glabrata (Anderson) Meyer& Yarrow 1978
 Synonymy: Torulopsis glabrata
Candida Krusei( castellani) Berkhout 1923
Synonymy : Saccharomyces Krusei / Endomyces Krusei
Teleomorph: Issatchenkia orientalis
Candida parapsilosis(Ashford) 1959
Synonym: Monilia parapsilosis
Candida tropicalis(Castellani)Berkhout 1923
Synonymy : Monilia tropicalis /  Oidium tropicalis
Candida Kefyr (castellani) Basgal 1931
Synonymy : Candida pseudotropicalis / Monilia pseudotropicalis
Teleomorph: Kluvyveromyces marxianus
Candida lusitaniae Teleomorph: Clavispora lusitaniae62
Candida dubliniensis [Sullivan et at 1993,1995]
Candida viswanathii Sandhu et randhawa 195987
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Epidemiology
Although most Candida spp. have been isolated from lower animals and 
environmental sources, human infections are usually endogenous .They reside 
primarily in the gastrointestinal tract but can also be found as commensals in 
the vagina and on  the skin.  Candida albicans is the most commonly isolated 
species from all these sites51.
As summarized by Odds, the range of C.albicans isolation from the oral 
cavity  is  1.9-41.4%, the  gastrointestinal  tract  is  0-55% and the  vagina  2.2-
68%.The same study indicates that the mean values of data from a number of 
epidemiological surveys reveal that C.tropicalis and C.glabrata are the second 
most frequent species isolated ; the former from the oropharynx and the latter 
from the vagina and the GI tract72,94.
          Oral carriage rates may be higher in certain settings such as HIV infected  
patients with CD4 count less than 500/µl, denture users with denture stomatitis, 
persons  with  diabetes,  patients  receiving  chemotherapy  for  malignant 
conditions and children. Among persons with diabetes , local factors such as 
smoking  and  the  presence  of  dentures  additionally  promotes Candida 
colonization of the mouth77.
Most epidemiological studies indicates that infections caused by non- 
C.albicans yeast  species  tend  to  become  more  prevalent  relative  to  those 
caused  by  C.albicans38.  Nevertheless, Candida  albicans is  still  the  most 
frequent  etiological  agent  of  candidiasis91.  Oropharyngeal Candidiasis  is  the 
most frequent form , occurring in upto 90% of persons with advanced untreated 
HIV infection33.Oesophageal Candidiasis occurs less frequently (10-20%) but 
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is  the leading cause of  oesophageal  disease67.  Vaginal Candidiasis  has been 
noted  in  27-60% of  women.  However  the  incidence of  vaginal  Candidiasis 
appears to be similar in HIV and HIV uninfected women96. 
Pathogenicity and pathogenesis
Virulence factors
Candida sp that  are normal flora can invade tissues and produce life 
threatening infections in patients whose immune defenses have been altered by 
diseases  and iatrogenic  intervention72,57.Candida  albicans the  most  common 
species isolated from all forms of Candidiasis appears to possess a number of 
virulence determinants. These  includes
(i) The  ability of the fungus to adhere to host tissues
(ii) Production  of  proteolytic  enzyme  like  secretory  aspartyl 
proteases and phospholipase enzymes
(iii) Yeast hyphal morphogenetic transformation 
(iv) Phenotypic switching
(v) Various immunomodulatory effects of fungal determinants94.
Pathogenesis of Candidiasis
Candidiasis is mostly an endogenous infection arising from overgrowth 
of  the  fungus   inhabitating  the  normal  flora6.  The  Gastrointestinal  tract  is 
considered a major reservoir for candidiasis from which the fungus can invade 
the blood stream following damage to the GI mucosa causing deep seated / 
disseminated  infection93.It  is  believed  that  Candida  can  cross  the  intact  GI 
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mucosa by a process called persorption following fungal overgrowth due to 
excessive antibiotic treatment48.
However it may be occasionally acquired from exogenous sources (such 
as  catheters  or  prosthetic  devices)6.This  is  of  particular  importance  in  the 
development  of  deep  seated  and  systemic  candidiasis  as  most  of  these 
therapeutic modalities are used in compromised hosts whose defense system 
are unable to combat the introduced pathogen.
Once  Candida entered  blood  stream  whether  from  exogenous  or 
endogenous  source,  the  microorganisms  adheres  to  the  endothelial  surface 
before  dissemination  into  tissues93,74.  Person to  person transmission  may  be 
occasionally seen in cases such as oral candidiasis in neonates of mothers with 
vaginal candidiasis or endophthalmitis following corneal transplantation from 
an infected donor9.
Pathology
The  macroscopic  and  microscopic  appearance  of  lesions  caused  by 
Candida spp. is primarily influenced by the interaction of three factors:
• The site of infection
• The pathogenicity of the infecting microorganism and to a lesser extent 
its species
• The competence of the host’s immune system
Consequently  the  pathological  and  histopathological  features  of 
Candida infections are highly variable ;  the same microorganism can cause 
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dissimilar  pathological lesions  in patients whose immune system is intact and 
those who are in a state of immunosuppression.
Superficial Infections
Superficial infections result from invasion of the superficial layers of the 
skin  or  mucosa  by  the  microorganism.  Macroscopically  ,  characterized  by 
formation  of  a  grayish  plaque,  surrounded  by  edema94 .In  oral  thrush,  the 
pseudomembanous lesion is composed of necrotic material, white blood cells, 
commensal  bacteria,  yeasts,  pseudohyphae  and  loose  epithelial  cells.The 
fungus is restricted to stratum corneum of the affected area84. 
Deep infections
Several parenchymatous organs may be involved .These infections are 
characterized  by  microabscesses.  Granulomata  with  giant  cells  and 
lymphocytes may be formed in chronic infections94.
Clinical Manifestations
As  the  frequency  of  diseases  caused  by  Candida has  increased,  a 
relatively  large  number  of  manifestations  have  become  well  documented. 
Clinical entities may be divided into two large groups57,94
1. Mucocutaneous Candidiasis
(i)Mucosal
              - Oral Candidiasis(Thrush)          - Vaginal Candidiasis
       - Candida oesophagitis
(ii)Cutaneous
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- Generalised Cutaneous Candidiasis
- Erosio interdigitalis ,Candida folliculitis , balanitis
- Candida balanitis- Intertrigo ,Diaper rash
- Chronic mucocutaneous Candidiasis
(iii) Nail  - Paranychia , Onychomycosis
2.Deep Seated Candidiasis
  - Central Nervous System Candidiasis     -   Urinary tract Candidiasis
  - Respiratory tract Candidiasis                 -   Cardiovascular Candidiasis
  - Candida infection of Vasculature      -   Disseminated Candidiasis and
  - Ocular Candidiasis                            Candidemia51
  - Candida arthritis, Osteomyelitis, -  Candidiasis of Peritonum , Liver,
      Costochondritis, Myositis      Spleen and Gall bladder
ORAL CANDIDIASIS
 Oral candidiasis is the most prevalent opportunistic infections affecting 
the oral mucosa. Candida spp are part of the normal mouth flora  in 25-50% of 
healthy individuals. Candida albicans is the most frequent colonizer (70-80%) 
but any  of the non- albicans spp may be seen .Oropharyngeal Candidiasis on 
the  other  hand ,  goes  beyond mere carriage to  symptomatic  infection  94.  A 
number of predisposing factors have the capacity to convert Candida from the 
common flora( saphrophytic stage) to a pathogenic organism60-
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 Predisposing factors for oral candidiasis
           Local factors                           General  factors
Denture wearing                Immunosuppressive drugs/diseases
Smoking                            Chemotherapy   
Inhalation steroids             Endocrine disorder
Topical steroids                 Hematinic malignancies
Hyperkeratosis                  Malignancies60
CLASSIFICATION
Oral candidiasis can be classified as follows1,25
A- Acute candidiasis
1) Acute pseudomembranous candidiasis ( Thrush)
2) Acute atrophic candidiasis (Erythematous)
B- Chronic candidiasis
1) Chronic hyperplastic candidiasis ( candidial leukoplakia)
2) Denture induced candidiasis ( chronic atrophic candidiasis)
3) Median rhomboid glossitis
C- Angular cheilitis
Oral Candidiasis and HIV
Oropharyngeal  Candidiasis  occurs  in  three  quarters  of  all  those  who 
have HIV infection. In about one-third it tends to be recurrent and becomes 
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progressively  more  severe  with  increasing  immunodeficiency98.  Oral 
Colonisation  with  inherently  drug  resistant  organisms  is  more  common  in 
advanced HIV infection (CD4 <50 cells/ µl)32.
Candidal  infection  in  AIDS is  almost  exclusively  mucosal,  systemic 
invasion is rare and late event .Oropharyngeal and Vulvovaginal disease are the 
most common forms of mucocutaneous candidiasis in HIV patients33.
Candida albicans has  been identified as  the  most  common causative 
agent of oral Candidiasis which was recognized from the beginning of AIDS 
pandemic  as  an  early  expression  of  immunodeficiency  that  occurs  in  HIV 
infected patients.  Less frequently , C.  glabrata,  C.parapsilosis,  C.tropicalis,  
C.krusei and several other spp may cause the disease33. Recurrent disease is 
caused by the same strain of  Candida in about 50% of case , remaining 50% 
are  caused  by  the  new  strains  of  Candida  albicans or  new  species32.The 
majority  of  disease  is  caused  by  organisms  that  are  part  of  normal  flora, 
although rare cases of person to person transmission have been documented. 
Indeed ,  unexplained oral  candidiasis  in  previously  healthy adults  has  been 
considered an important clinical predictor of AIDS as well as highly predictive 
of worsening immunodeficiency7.
 Upto 90% of persons with advanced untreated HIV infection develop 
Oropharyngeal Candidiasis, with 60% having atleast one episode per year with 
frequent  recurrences(50-60%)32,11.Symptoms  of   Oropharyngeal  Candidiasis 
include burning pain, altered taste sensation, difficulty  in swallowing liquids / 
solids.  Many  patients  are  asymptomatic.  Most  commonly  present  with 
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pseudomembranous  candidiasis  and  less  commonly  with  other  forms  like 
erythematous, hyperplastic / angular cheilitis33,86.
LABORATORY DIAGNOSIS OF ORAL CANDIDIASIS
SPECIMEN COLLECTION
                   Specimens from patients with oral candidiasis can be collected by  
swabs63  and kept , preferably , in transport medium before being processed in 
the laboratory. Specimens from oral lesions can also be obtained by scraping94.
DIRECT EXAMINATION
The preferred method for the direct microscopic examination of  oral 
candidiasis  incudes  (i)  Wet  mount  (ii)  Fixed  mount  .  Processing  of  the 
specimen does not generally require treatment with keratinolytic substance.
           Wet mounts can be unstained , prepared in saline or stained with 
lactophenol cotton blue or calcofluor white.
           Microscopic examination of specimens from oral candidiasis will 
demonstrate   the  presence  of  budding  yeast  cells,  pseudohyphae  and/  or 
hyphae. Demonstration of hyphal elements in direct microscopic examination 
is  important  as  Candida  spp normally  colonises  the  oral  mucosa  and  the 
presence of the hyphal elements in addition to the yeasts , is an indicator of 
infection.  However  C.glabrata,  a  significant  non-albicans  species  does  not 
produce hyphae or pseudo hyphae in clinical specimens94.
CULTURAL CHARACTERISTICS: 
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Candida spp grow on almost all common laboratory media particularly 
blood agar and Sabouraud’s dextrose agar with antibacterial  antibiotics  for 
primary isolation27.
ISOLATION OF CANDIDA
Sabourauds  Dextrose  Agar with antibiotics
The  routine  medium  used  for  isolation  of  fungi  in  culture  from 
mucocutaneous  infections  is  Sabouraud’s  dextrose  agar  supplemented  with 
antibiotics  like  gentamycin  ,  chloramphenicol  or  tetracycline  to  prevent 
bacterial  overgrowth38.  The  addition  of  cycloheximide  to  inhibit  fungal 
contaminants permits the growth of Candida albicans but inhibits most strains 
of  C.tropicalis,  C.krusei  and C.parapsilosis.Use  of  two  SDA  containing 
chloramphenicol  supplemented  with  or  without  cycloheximide  is 
recommended94.
Cultures can be incubated at 28 C or / and at 37 C.⁰ ⁰ Candida colonies 
appears in two to three days and more than three days for some Candida spp 
like C. guillermondii and C.glabrata.
Colony Characteristics and Microscopic Morphology of Candida on SDA
• Candida albicans
Macroscopically  –  Colonies  are  smooth  ,  creamy  ,  pasty  ,  glistening 
Microscopically – globose or short ovoid cells(5 - 7 µm),
• Candida tropicalis
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Macroscopically – white to cream coloured colonies with  peripheral  fringe 
Microscopically – globose – ovoid or short ovoid cells (4 -8 µm X 5-11 µm)
• Candida krusei
Macroscopically  - Colonies are flat ,dry becoming dull, smooth or wrinkled 
with the dense of mycelium extending as lateral fringe around the colony
Microscopically - Cylindrical , few ovoid cells / elongated cells (3-5 µm x 6-20 
µm) 
• Candida parapsilosis
Macroscopically  – Soft, smooth, white sometimes lacy
Microscopically   –  Short ovoid to long ovoid cells ( 2.5 - 4µm  x  2.5 -9 µm)
• Candida guilliermondii
Macroscopically  – Thin , flat, glossy , cream to pinkish colonies
Microscopically  - short ovoid / ovoid cells( 2-5 µm x 3-7 µm)
• Candida glabrata
Macroscopically-Cream coloured, soft, glossy ,smooth colony
Microscopically-small, round yeasts (2.5 – 4.5 µm x 4-6 µm)
• Candida kefyr
Macroscopically- Smooth , creamy appearance
Microscopically-  short,  ovoid  with  a  few  elongate  cells(2.5  -5  µm  x  5-10 
µm)34,84
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CHROM agar
A new differential culture that allows selective isolation of yeasts and 
presumptive identification of most commonly isolated Candida spp especially 
Candida albicans,  Candida tropicalis and  Candida krusei65.Identification  of 
yeast  pathogen  by  traditional  methods  requires  several  days  and  specific 
mycological media. Chromogenic media contain chromogenic substrates which 
react with enzymes secreted by the target microorganisms to yield colonies of 
varying colours after incubation at 37  C for 48 to 72 hours⁰ 39.
Cornmeal Agar
The commonly used differential medium both for genus identification as 
well as speciation is the Corn meal Agar plate( Dalmau plate) supplemented 
with Tween 80 (Polysorbate 80)  or Rice starch agar24.
Corn meal agar is a general purpose medium used for the isolation of 
fungi . In 1960, Walker and Huppert modified the basic formulation by adding 
polysorbate 80 which stimulated rapid and abundant chlamydospore formation. 
Dextrose is added to Corn meal agar to enhance fungal growth and pigment 
production.
Subcultures  made  by  furrowing  the  Corn  meal  agar  plates  with 
coverslips applied on the streak line and incubated at 28 C for 2-5 days.Cover⁰  
slips applied provides an anaerobic environment which enhances the formation 
of hyphae and blastoconidia and the polysorbate 80 reduces the surface tension.
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After 2-5 days of incubation , plates are examined  directly under the 
microscope for the presence of  pseudo hyphae/ true hyphae, chlamydospores , 
arthroconidia, blastoconidia.
Chlamydospore  formation  are  seen  in  the  isolates  of  C.albicans and 
C.dubliniensis.  C.dubliniensis  often  produces  chlamydospores  abundantly  in 
clusters.
Microscopic Morphology of different species on Corn Meal Agar
C.albicans –Hyphae  and  pseudohyphae  formed  with  clusters  of 
blastospores at internodes and large thick walled terminal chlamydospores
C.tropicalis- Abundant long , branching pseudohyphae .Ovoid / elongate 
pseudohyphae found anywhere along the pseudohyphae .True hyphae may be 
present.
C.krusei  –  Pseudohyphae  with  elongated  blastoconidia  in  tree  like 
arrangements / Crossed match stick appearance
C.parapsilosis-  Fine pseudomycelium with single or small clusters of 
blastoconidia.Thick pseudo mycelium and giant cells also found.
C.glabrata –No pseudohyphae.Small,  spherical and tightly compacted 
blastoconidia
C.guilliermondi –Pseudohyphae with blastospores in small chains or in 
clusters
C.kefyr –Abundant pseudomycelium of elongate cells  that  lie  parallel 
giving log in stream appearance. Blastoconidia are infrequent84,34,4.
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Growth in Sabourauds Dextrose broth
Serves  as  an  important  differentiating  method  for  various  Candida 
species.  Ring around the surface of the tube at the broth interface indicates 
Candida tropicalis , a thick pellicle creeping along the sides indicates C.krusei 
while growth occurring at the bottom indicates other Candida species84.
Germ Tube Test (Reynolds Braude Phenomenon)
A germ tube is defined as a filamentous extension from a yeast cell that 
is about half  the width and three to four times the length of the cell28.  The 
principle of the test is the ability of Candida albicans or Candida dubliniensis  
to produce blastospores when incubated in serum at 37 C for two hours⁰ 94. It 
helps  in  the  presumptive  identification  of  Candida  albicans43 or Candida 
dubliniensis94,44.  A true germ tube has no constriction at the point of origin. 
Early  pseudohyphae  of  Candida  tropicalis may  be  confused  but 
characteristically show a point of constriction adjacent to the mother cell28.
Taschdjian et al in  1960 reported that  C.albicans and its variants are 
able to produce germ tube when incubated with various substances like human 
or sheep serum, rabbit plasma , egg albumin, thioglycollate broth and various 
peptone medium at 37 C for 2 hours⁰ 61.
A new  Monoclonal  Ab  specific  for  C.albicans germ  tube  has  been 
described. Hydrophobic components of the germ tube of C.albicans were used 
as antigens to prepare monoclonal antibodies. MAb-16B1F10 was shown by 
indirect IF to be specific to the surface of the mycelium phase of the C.albicans 
and C.stellatoidea but not with the species C.dubliniensis. The identification of 
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this antigen on the surface of the mycelial phase of  C.albicans cells could be 
powerful tool for diagnostics and especially for differentiation of C.albicans 
and C.dubliniensis53 . 
Biochemical Characterisation
Biochemical speciation of candida is based on 
1) Assimilation       2) Fermentation tests.
Candida  species can  utilize  carbohydrates  both  oxidatively 
(assimilation) & anaerobically  (fermentation) .Yeasts possessing the ability to 
ferment  a  given  carbohydrate  do  also  assimilate  that  substance  but  not 
necessarily vice versa94.
1. Sugar assimilation tests:
Sugar assimilation determines the ability of a particular yeast to utilize a 
particular  carbohydrate   as  the  sole  source  of  carbon  in  the  presence  of 
oxygen35.  Carbohydrate  utilization  patterns  are  the  most  commonly  used 
conventional methods for the definitive identification of yeast recovered in a 
clinical laboratory4.
Various techniques:
• Classic  Wickerham  method  (By  Wickerham  &  Burton  1948)  , 
assesses  assimilation  by  determining  the  ability  of  a  given  Yeast 
isolate to grow in a broth supplemented with carbohydrates97. 
• Auxanographic methods:-
This technique employs minimal media agar plates on which paper disc 
impregnated with different carbohydrates are placed and the growth ability of 
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the yeast around a specific disc is an indication of the yeast ability to assimilate 
the carbohydrate94,44.  
• Commercial Kits
Modification  of  the  auxanographic  assimilation  technique  and  have 
replaced the  conventional  methods.  Commonly used are  API 20c,  API 32c, 
micro-drop assimilation test system and uni-yeast-tek system ,Vitek, Minitek 
etc46,94.
2. Sugar fermentation test:
The  classic  tests  involved  liquid  media  supplemented  with  different 
carbohydrates,  a  colour  indicator  to  assess  pH  changes  to  measure  acid 
formation and the Durham’s tube to assess gas production .There are several 
modifications for assessment of gas production such as use of semisolid media 
or a wax layer on top of liquid medium. Production of gas and not the change 
of colour in the fermentation fluid is considered as the indicator of positive 
fermentation94,56. 
OTHER METHODS
SEROLOGY
Candida spp. can also be identified serologically, using specific antisera. 
A commercial available  set of sera (iatron system), prepared against cell wall 
antigens  enables  quick  species  identification  of  the  commonly  encountered 
pathogenic Candida spp. by simple slide  agglutination tests. 
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MOLECULAR METHODS 
i) Use of specific DNA probes like those encoding for actin gene, 
14-lanosterol demethylase, part of the 18s RNA gene complex, 
chitin  synthetase  gene,  mitochondrial  DNA or  Candida  DNA 
Repititive Elements (CARE)
ii) Electrophoretic patterns of DNA
iii) RNA profiling
iv Restriction enzyme analysis
v Amplification techniques like Polymerase chain reaction94.
ANTIFUNGAL SUSCEPTIBILITY TESTING
The rising prevalence of serious fungal infections and antifungal drug 
resistance has created an increased demand for reliable methods of  in vitro 
testing of antifungal agents that can assist in their clinical use46.
Invitro susceptibility tests
1. Provides a reliable measure of the relative activities  of two or 
more antifungal agents 
2. Correlate with invivo activity and predict the likely outcome of 
therapy
3. Provides  a  means  with  which  to  monitor  the  development  of 
resistance among a normally susceptible population of organisms.
4. Predict  the  therapeutic  potential  of  newly  discovered 
investigational agents67.
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Methods used for in vitro antifungal susceptibility testing of Yeasts are
1) Agar based method
 Disk Diffusion
 Agar macrodilution
 E-test
2) Broth based methods
 Macrodilution
 Microdilution
 Colorimetric microdilution
3) Others
Neosensitabs tablets 
EUCAST method,   Spectrophotometric
Flowcytometer,   Fungitest67
The CLSI (formerly NCCLS) subcommittee on Antifungal susceptibility 
testing has  developed reference methods for  broth macro and microdilution 
susceptibility testing of Yeast (CLSI M27-A3 document) and more recently a 
disk diffusion method for Yeasts (CLSI M44 A document).
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Broth microdilution:
           Although the antifungal broth macrodilution test was the first method 
proposed by the CLSI, this test is cumbersome for use in clinical laboratory. 
The broth microdilution has become the most widely used technique.
CLSI  recommends  RPMI  1640  medium  with  L-glutamine,  without 
sodium bicarbonate  and buffered  with  morpholine  propane  sulfonic  acid  at 
0.165M as the test medium .Yeast inocula standardized spectrophotometrically 
and diluted in RPMI medium to obtain a final concentration of 0.5 to 2.5 * 103 
CFU/ml .
In microbroth dilution, 100µl of each antifungal agent at a concentration 
two times the targeted final concentration were dispensed in the wells of flat 
bottom 96 well micro titre plates. A constant volume (100 µl) of inoculum was 
added to each micro dilution well containing 100 µl  of serial dilution of the 
antifungal agents to reach final concentration and incubated at 35ºC for 48 hrs 
for Candida36,21. In macrobroth, 0.1 ml of antifungal drug, containing 10 times 
the final targeted concentration was dispensed in test tubes and 0.9 ml of the 
inoculums added to the serial dilution of the antifungal agents12.
    Drug dilution range 
1) Fluconazole                                 64 to 0.12  µg/ml
2) Amphotericin, itraconazole          16 to 0.03 µg /ml 
Clotrimazole, Nystatin68
MIC of polyene fungals ( Amphotericin, nystatin) defined as the lowest 
concentration that inhibit growth by 100%.
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MIC of  azoles  were  defined  as  the  lowest  concentration  that  inhibit 
growth by 50% in microbroth & 80% in macrobroth dilution21,46.
Interpretation21 :
Susceptible Susceptible Dose 
Dependent
Resistant
Fluconazole ≤ 8µg/ml 16-32 µg/ml ≥ 64 µg/ml
Itraconazole ≤ 0.125 µg/ml 0.25-0.5 µg/ml ≥ 1 µg/ml
Broth based alternative approaches for yeasts 
Colorimetric methods
A novel alternative to the standard method of visual grading of turbidity 
is the use of colorimetric methods or fluorescent dyes for the determination of 
MIC  endpoints.  Commercial  (Sensititre  Yeast  one  and  fungitest)  and 
noncommercial (tetrazolium salt  methods and substrate uptake indicator has 
been adapted for susceptibility testing)30,46.
Spectrophotometric methods
The  spectrophotometric  approach  to  MIC  end  point  determination 
provides  an  objective  and rapid  MIC reading and eliminates  the  subjective 
judgements concerning minimal turbidity .Spectrophotometric MICs reflecting 
either a ≥ 50% inhibition or a ≥ 70% inhibition of growth relative to control 
growth provides  a  good agreement  with the  NCCLS reference methods for 
fluconazole and other azoles76.
Flow cytometry
Flow  cytometric  methods  have  been  adapted  for  Antifungal 
susceptibility testing by introducing DNA- binding vital dyes into the culture to 
detect fungal cell damage after exposure to an antifungal agent. Inspite of faster 
results,the need for flow cytometer preclude their use in small laboratories68.
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Agar based methods
Disk Diffusion method 
Agar disk diffusion is a simple, flexible and cost effective alternative to 
broth  dilution  testing  67.  CLSI  subcommittee  has  proposed  a  standard  disk 
diffusion method for susceptibility testing of Candida spp to the Fluconazole, 
Posaconazole  and  Voriconazole.  The  subcommittee  has  established  zone 
interpretative criteria for Fluconazole and Voriconazole . Recommends MHA 
medium supplemented with 2% glucose and 0.5µg/ml of methylene blue and 
the inoculums size of 0.5 Mcfarland standard and incubation temperature of 
35  C  for  20  to  24  hr  and  some  strains  may  require  48  hr⁰  
incubation68,20.Addition of a low concentration of methylene blue (0.5µg/ml) 
make the zones of inhibition clearer and easier to measure precisely8,60.
Agar based alternative approaches
1) Neosensitabs tablets
Tablets  of established and some of  the new antifungal agents  are available. 
Preliminary comparisons with both M27-A2 and M44A methods have provided 
promising results29.
2) Epsilometer test (E- test)
E-test uses a non-porous plastic strip immobilised with a predefined gradient of 
a given antimicrobial agent on one side and printed with an MIC on the other 
side.  The  medium  that  provides  the  best  performance  for  E-test  MICs  is 
solidified RPMI supplemented with 2% dextrose. When the strip is placed on 
an inoculated agar plate, a continuous , stable and exponential antimicrobial 
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gradient is established along the side of the strip. After incubation, the MIC 
value can be read directly from the MIC scale printed on the strip68.     
TREATMENT OF ORAL CANDIDIASIS
(i)Mild:
Clotrimazole troches at a dosage of 10mg 5 times daily,
Nystatin at a concentration of 10000 U/ml, dosage of 4-6ml 4 times daily
(ii)Moderate to severe:
Oral Fluconazole:100-200mg daily for 7-14 days
(iii)Fluconazole refractory Candidiasis 
Itraconazole: 200mg daily for 14 days
Intravenous echinocandins or Amphotericin –B at a  dosage of 0.3mg/kg daily
(iv) Chronic suppressive therapy is usually not necessary for HIV infection.If 
needed, fluconazole at a dosage of 100mg 3 times daily is recommended.
In HIV patients, the use of HAART has been associated with decreasing 
rates  of  oral  carriage  of  Candida  albicans and  reduced  frequency  of 
symptomatic  oropharyngeal  candidiasis.Thus,  HAART  should  be  used  as 
adjunctive  therapy  whenever  possible  for  all  HIV  infected  patients  with 
oropharyngeal or oesophageal Candidiasis75.
ANTI FUNGAL DRUG RESISTANCE
The antifungal drug resistance can be divided into two types:
(a) Clinical resistance
(b) InVitro resistance:        Intrinsic /primary resistance
                                     Acquired / Secondary Resistance42 
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Clinical Resistance
Clinical failure to respond to an antifungal agent occurs due to many 
causes. A major problem for patients with HIV infection is the improper use of 
prescribed  medications  .  Clinical  failures  may  also  result  from  inadequate 
absorption  of  an  antifungal  medication.  Drug  interaction  can  also  result  in 
decreased level of antifungal metabolites31
Intrinsic Resistance 
Intrinsic  resistance  is  an  inherited  characteristic  of  a  species  or  a 
strain.This  innate  level  of  susceptibility  is  thought  to  be  a  drug  organism 
characteristic and independent of drug exposure. 
Acquired /Secondary Resistance:
Acquired  resistance  occurs  when  a  previously  susceptible  isolate 
develops a resistant phenotype, usually as a result of prolonged treatment with 
antifungals93.
Azole Resistant Candidiasis
                The development of resistance to azole antifungals in yeasts is a 
recent phenomenon.It is usually associated with Candida albicans.  
• Acquired azole resistance
One of the consequences of continuous suppressive antifungal therapy 
in HIV patients has been the emergence of resistant disease .Resistance has 
been  described  both  to  fluconazole  and  itraconazole  and  tends  to  occur  in 
persons with advanced HIV disease with CD4+ count < 50/mm , who have 
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been exposed to  antifungal  therapy on a  chronic  basis58.  Resistant  strain of 
Candida albicans were found in 20 to 33% of symptomatic oral candidiasis 
patients with HIV and upto 14% of asymptomatic patients with HIV93.
• Intrinsic azole resistance
Patients  on  fluconazole  suppressive  therapy  are  more  likely  to  have 
infection   caused  by  non  –albicans  species such  as  Candida  krusei and 
Candida glabrata which are intrinsically resistant to fluconazole58.
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AIMS AND OBJECTIVES
1. To isolate Candida species from HIV patients with oropharyngeal 
Candidiasis.
2. To speciate the Candida isolates.
3. To determine the antifungal susceptibility pattern of the isolates 
by disk diffusion and microbroth dilution method.
4. To find out the correlation of various Candida isolates and their 
antifungal susceptibility pattern to the CD4 count of the patients.
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MATERIALS AND METHODS
STUDY PERIOD
This is a cross sectional study undertaken over period of June 2008 –
May 2009
STUDY PLACE
 This study was carried out at the Institute of Microbiology , Madras 
Medical College , Chennai and Antiretroviral therapy (ART) centre , Madras 
Medical College and Government General Hospital, Chennai.
ETHICAL CONSIDERATIONS
The  study  was  reviewed  and  approved  by  the  Institutional  Ethical 
Committee, Madras Medical College and General Hospital, Chennai-3.
STATISTICAL ANALYSIS
Statistical analysis were carried out using statistical package for Social 
sciences and Epi- software by statistician .The proportional data of this cross 
sectional  study  were  tested  using  Pearson’s  Chi  Square  Analysis  test  and 
Binomial Proportion test.
STUDY GROUP
Study group includes 150 HIV positive patients presenting with clinical 
picture of oral candidiasis 
Inclusion Criteria  
1. HIV positive patients: Seropositivity status of the patients were 
determined as per NACO guidelines. 
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2. Patients  with  clinical  picture  of  candidiasis  on  the  oral  / 
pharyngeal mucosa.
3. Patients above 18 years of age group.
4. Both Males and Female were included in the study.
5. Not  on any antifungals  or  corticosteroids  30 days  prior  to  the 
study.
Patients were included in the study only after getting informed written 
consent.
All patients satisfying the inclusion criteria were only once documented 
and were assigned serial numbers.
Patients were interviewed by structured questionnaire and their hospital 
records  were  used  to  know about  the  previous  episodes  of  Oropharyngeal 
Candidiasis, use of any antifungal agents and past medical conditions.
SPECIMEN COLLECTION
Oropharyngeal specimens were collected by firmly swabbing the lesion 
site with two steile cotton swabs under strict aseptic precautions.
Samples were transported immediately to the laboratory and subjected 
to various mycological tests.
Blood was collected in EDTA vacutainer tubes from each patients for 
enumeration of their CD4 count using BD FACS Counter.
SPECIMEN PROCESSING
Specimens collected were subjected to standard mycological procedures.
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Direct Microscopic examination
One swab  was used for the direct microscopic examination by Gram 
stain. For each specimen , smears were made on a dry, clean glass slide, air 
dried and heat fixed . The fixed smears were stained by Gram staining method 
and  observed  under  the  oil  immersion  for  the  presence  of  gram  positive 
budding yeast cells with or without pseudohyphae94.
Culture  on Sabourauds Dextrose Agar
The culture medium used was Sabourauds Dextrose Agar with pH 5.6 
supplemented with antibiotics like gentamycin and chloramphenicol to prevent 
bacterial overgrowth .Second swab was inoculated immediately into the plates 
and incubated at 28 C and 37 C for 24-72 hours⁰ ⁰ 94. 
            Isolates were identified by colony morphology on SDA plates. Growth 
appears  in  2  to  3  days  as  creamy,  white  pasty  colonies  .The  microscopic 
morphology of the colony on Gram stain was noted.
Species identification
Isolates were speciated based on the following tests:
Germ Tube Test
• 0.5ml of human serum was taken in a sterile test tube.
• A small portion of an isolated colony of the yeast to be tested was 
inoculated into the human serum.
• The test tube was incubated at 37 C for two hours.⁰
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• After two hours of incubation , a drop of the yeast serum suspension 
was placed on a microscopic slide , overlaid with a cover slip and 
examined microscopically for the presence of germ tube under low 
power microscope.
• If the test was positive within two hours, the isolate was considered 
presumptively as Candida albicans / Candida dubliniensis28,94.
Growth at 42 C⁰
All germ tube positive isolates were subcultured on SDA and incubated 
aerobically  at  42 C,  to  distinguish  between  ⁰ Candida albicans and  Candida 
dubliniensis91,99.
Candida albicans Candida dubliniensis
Growth at 42 C⁰ Present Scanty / Absent
Corn Meal Tween 80 Agar (Dalmau Plate Culture Technique) 
• An isolated colony from the primary culture media was taken using a 
straight wire and inoculated into cornmeal agar plate containing 1% 
Tween 80 by making three parallel lines about half an inch apart at 
an 45  angle to the culture media.⁰
• A sterile cover slip was placed over the surface of the agar, covering 
a portion of the inoculated streaks.
• Plate was incubated at 28 C for 48 hours.⁰
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• After 48 hours , the areas where the cuts into the agar made, were 
examined first  under the low power objective and then under the 
high power objective for the presence of
 *  Hyphae - true or pseudohyphae* Blastoconidia
* Arthroconidia  * Chlamyoconidia4   
Candida CHROM agar
• Isolates were subcultured twice on Sabourauds Dextrose agar prior 
to inoculation on chromogenic media.
• A single yeast colony was streaked onto the plates.
• Plates were incubated at 37  C  in the dark.⁰
• The results were read after 48 hours and the colour of the colony was 
noted.
• This  helps  in  the  presumptive  identification  of  most  commonly 
isolated  Candida  species especially  Candida  albicans,  Candida 
tropicalis, Candida krusei.
Candida albicans             -         Light green
Candida tropicalis           -         Steel blue with pink hallow
Candida krusei                 -         Pink
Candida parapsilosis       -         Cream coloured
Candida glabrata             -          Purple
Candida dubliniensis      -         Dark green
           Candida guilliermondii   -           Pale pink to purple65 .
Sugar fermentation test (APPENDIX XII)
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• A loopful  of  24-48  hours  culture  from  a  sugar  free  media  was 
suspended in sterile distilled water.
• 0.2 ml of this suspension was added to 2% sugar fermentation media 
with bromothymol blue indicator.
• Dextrose, Lactose, Sucrose and Maltose sugars were tested.
• Inoculated sugar tubes were incubated at 30  c for 48 to 72 hrs.⁰
• The ability to ferment a sugar was noted by the presence of acid and 
gas trapped in Durham’s tube56.
Sugar Assimilation test (APPENDIX XI)
• A yeast suspension was made from a 24-48 hrs culture grown in a 
sugar free media, in to 2 ml of Yeast Nitrogen base by adding heavy 
inoculums.
• The suspension was added to 18 ml of molten agar cooled to 45  c⁰  
and mixed well and  the entire volume was poured in to a 90 mm 
sterile petri plate.
• The  plate  was  allowed  to  set  at  room temperature  until  the  agar 
surface hardens.
• With the help of sterile forceps ,carbohydrate discs [ Hi-media] like 
dextrose,  sucrose,  lactose,  raffinose,  trehalose  were  placed on the 
surface of the inoculated agar.
51
• The plates were incubated at 30  c for 24-48 hr and were observed⁰  
for  the  growth  of  yeast  around  the  sugar  discs,  indicating 
assimilation of that particular carbohydrate.
• Each  Candida species utilizes specific carbohydrate substrate and 
the  characteristic  carbohydrate  profiles  were  used  to  identify  the 
species27,4.
Antifungal Susceptibility testing
Antifungal susceptibility  test for the  Candida isolates was done by
(i) Disk Diffusion method
(ii) Microbroth dilution method, as per the CLSI guidelines on 
antifungal Susceptibility testing in M44-A document and 
M27-A2 document repectively.
Inoculum Preparation (Stock Suspension Preparation)
• Candida  isolates  to  be  tested  were  grown on SDA at  35  C and⁰  
subcultured atleast twice to ensure purity and viability.
•  The inoculum  suspension was prepared by  picking five colonies of 
1mm diameter  from a 24 hour  old culture  and suspended in 5ml 
sterile 0.85% NaCl.
• The  turbidity  of  the  cell  suspension  was  adjusted  to  85% 
transmittance at 530nm using a spectrophotometer by adding sterile 
0.85% NaCl  as necessary.
• The resulting stock suspension contains 1 x 106   to 5 x 106   yeast 
cells/ml. 
Disk Diffusion Method
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Medium :
Mueller  Hinton  Agar  supplemented  with  2%  dextrose  and  0.5µg/ml 
methylene blue was used
Procedure:
• Optimally  within  15  minutes  after  adjusting  the  turbidity  of  the 
inoculum suspension, a sterile cotton was dipped into the undiluted 
inoculum suspension.
• The excess  fluid  from the swab was removed by firmly  pressing 
against the inner wall of the tube above the fluid level .
• The dried surface of the plate was inoculated by evenly streaking the 
surface in three different directions , rotating the plate approximately 
60  each time to ensure an even distribution of inoculums .As the⁰  
final step , the rim of the agar was swabbed.
• The plate was allowed to dry for 3 to 5 minutes and not more than 15 
minutes.Using a pair of flame sterilised forceps, the antifungal discs 
were applied on the surface of the inoculated plates.
• The following antifungal discs were used
Fluconazole 25µg                        Nystatin10 µg
Amphotericin 100U             Ketaconazole10 µg
Itraconazole 10 µg          Clotrimazole10 µg
• The plates were inverted and incubated at 35  C within 15 minutes⁰  
after the disks were applied.
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• Plates were examined after  20 to  24 hours  of incubation.  In  case 
insufficient growth, plates were read at 48 hours .
• The resulting zones of inhibition was measured to the nearest whole 
millimeter  at  the  point  where  there  was  prominent  reduction  in 
growth20.
• Interpretation71
Drug Susceptible SDD Resistant
Fluconazole (25 µg) ≥ 19 mm 15-18 mm ≤ 14mm
Itraconazole (10 µg) ≥ 20mm 12- 19mm ≤ 11 mm
Amphotericin B(100 
U)
>10mm Not applicable ≤ 10mm
Susceptibility  pattern  of  the  Candida  isolates  for  ketaconazole  , 
clotrimazole and nystatin were determined by comparison with the standard 
control strains42.
Susceptible  : Zone diameter of test strain is more than 80% of control strain
Intermediate : Zone diameter of test strain is less than 80% of control strain
Resistant :  No zone of inhibition42.
* Following  standard  strains  were  tested  each  time  to  ensure  quality 
control
Candida albicans ATCC 90028       Candida parapsilosis ATCC 22019
Candida tropicalis ATCC 750            Candida krusei ATCC 6258 20
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Microbroth Dilution Method
Medium
RPMI 1640 medium with  glutamine  ,  without  bicarbonate  in  MOPS 
(3N-Morpholino  propane  sulphonic  acid),  buffer  sterilized  by  membrane 
filtration.
Inoculum preparation
• The stock  suspension (1 x 106   to 5 x 106  yeast cells/ml)  prepared 
was further diluted to 1:1000 in RPMI medium to obtain a inoculum 
which contains 1 x 103   to 5 x   103/ml.This inoculum was  further 
diluted 1:1  when the wells are inoculated to achieve the final desired 
inoculums size containing 0.5 x 103  to 2.5 x 103/ml
Antifungal Stock Solution
The MIC range of antifungal agents used  were
(i) Fluconazole  : 64 -0.125µg/ml
(ii) Itraconazole , Amphotericin -B: 16-0.031 µg/ml
Fluconazole  was  dissolved  in  sterile  distilled  water  whereas 
amphotericin B and itraconazole were dissolved in DMSO. From the working 
dilution, the desired concentrations were prepared
Procedure
• The test was perfomed in a sterile , disposable ,96 well microdilution 
plate using standard RPMI 1640 medium.
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• The  2 x drug concentration in 100µl volume was dispensed into the 
wells of row 1 to of the microdilution plate using a multichannel 
pipette.
• Row 1 contains the highest drug concentration and row 10 contains 
the lowest drug concentration.
• Each  well  was  inoculated  with  the  100  µl  of  2  x  inoculums 
suspension which brings the inoculums densities and drug dilutions 
to the final concentration.
• The growth control well contains 100 µl of sterile drug free medium 
and  was  inoculated  with  corresponding  diluted  2  x  inoculums 
suspensions.
• Row 11 was used to perform the sterility control containing only the 
drug free medium only
• The Quality control strains was tested in the same manner.
• The plates were incubated at 35  C for 48 hours⁰ 21.
Interpretation
The plates were observed for the presence or absence of visible growth. 
Agitations  of  the  microdilution  plates  prior  to  MIC  determination  is 
recommended . The growth in each well was compared with the growth control 
drug free well.
A numerical score which ranges from 0 to 4 was given to each well
1 -  Optically clear
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2 -  slightly hazy or approximately 25% of growth control
3 -  prominent decrease in turbidity or approximately 50% of  
growth control
4 - slight  reduction  in  turbidity  or  approximately  80%  of  
growth control
5 – no reduction in turbidity
End point of MIC
Fluconazole  and  Itraconazole  -  Score 2 or less
Amphotericin - Score 0
Quality control strains used were
Candida parapsilosis ATCC 22019 
Candida krusei ATCC 625821.
Enumeration of CD4 + T cells
• Estimation of CD4+ T lymphocyte of the HIV infected patients was 
done by Fluorescent Activated Cell Sorter (FACS) count system.
• Blood sample was collected aseptically in a K3 EDTA Vacutainer 
tube.
• 50µl  of  whole  blood  was  added  to  the  reagent  tube  containing 
fluorescent  labelled  antibodies  which  results  in  the  binding  of 
labelled monoclonal antibodies to the lymphocyte surface antigen.
• After adding fixative solution to the reagent tube, the sample was run 
in the instrument.
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• The  cell  comes  in  contact  with  the  laser  beam which  causes  the 
fluorochrome labelled antibodies to fluoresce.
• The  fluorescent  light  provides  the  information  necessary  for  the 
instrument to count the cells.
• The  software  identifies  the  T-  lymphocyte  subpopulation  and 
correlates with the absolute count
• Results provides the absolute counts of CD4+ lymphocyte23.
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RESULTS
This cross sectional study was carried out during the period June 2008 
to  May  2009  in  the  Institute  of  Microbiology,  Madras  Medical  College, 
Chennai .Speciation   of the Candida isolates from 150 HIV patients with Oral 
Candidiasis was done and antifungal susceptibility pattern of the isolates were 
determined by disk diffusion and micro broth dilution method. 
TABLE - 1
AGE DISTRIBUTION OF HIV PATIENTS WITH OROPHARYNGEAL 
CANDIDIASIS (n=150)
Age(Years) Total No. of cases Percentage
18-28 26 17.33
29-39 64 42.66
40-50 48 32
51-61 09 6
>62 03 2
Total 150 100
Majority of the study population belonged to the age group of 29-39 
years(42.66%)
TABLE-2
GENDER DISTRIBUTION OF HIV PATIENTS WITH 
OROPHARYNGEAL CANDIDIASIS (n=150)
GENDER NUMBER PERCENT
MALE 103 69
FEMALE 47 31
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TOTAL 150 100
Table I shows that male patients outnumbered female patients.
TABLE - 3
TYPE OF LESIONS IN HIV PATIENTS WITH OROPHARYNGEAL 
CANDIDIASIS (n=150)
Type of Lesion No of 
Patients
Percentage
Pseudomembranous lesions 93 62
Pseudomembranous & Erythematous 42 28
Pseudomembranous  with  Angular 
cheilitis
7 4.6
Hyperplastic 4 2.7
Erythematous 4 2.7
Total 150 100
Majority of the patients had pseudomembranous type of lesion (62%), 
followed by pseudomembranous and erythematous type of lesion(28%).
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TABLE - 4
DISTRIBUTION OF HIV PATIENTS WITH OROPHARYNGEAL 
CANDIDIASIS WITH/WITHOUT HAART
TREATMENT No.of Patients Percentage
On HAART          43     28.7
Not on HAART        107     71.3    
Total        150    100
 
28.7% of the patients were under HAART and 71.3% of the patients 
were not on HAART. Majority of the patients were on HAART for duration 
below 3 months.
TABLE-5
CULTURE POSITIVITY IN HIV PATIENTS WITH 
OROPHARYNGEAL CANDIDIASIS (n=150)
Total no. of 
samples
No. of culture 
positive samples
Percentage of 
culture 
positivity
Total no of 
isolates
150 150 100 152
Out of 150 samples, 152 isolates were isolated with a culture positivity 
of 100%
TABLE-6
DISTRIBUTION OF THE CANDIDA ISOLATES (n=152)
Number of isolates Percent
Single 148 97.4
Mixture 4 02.6
Total 152 100
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Of the 150 samples, two revealed a mixture of two species accounting 
for the 152 isolates.
TABLE - 7
DISTRIBUTION OF THE CANDIDA ALBICANS AND 
NON –ALBICANS ISOLATES (n=152)
No.of isolates Percentage
Candida 
albicans
       118     78
Non  albicans 
Candida(NAC)
         34     22
Total        152     100
        Candida albicans was the most frequently isolated species accounting for 
78% and the remaining were non- albicans accounting for the 22%.
TABLE - 8
SPECIES DISTRIBUTION OF THE CANDIDA ISOLATES (n=152)
Species Total no Percentage
Candida albicans     118        78
Candida tropicalis       17        11
Candida krusei         8        5
Candida parapsilosis        6         4
Candida glabrata        2         1
Candida guilliermondii        1         1
Total      152       100
Among the non-albicans Candida sp, Candida tropicalis was the most 
common species isolated.
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TABLE-9
DISTRIBUTION OF PATIENTS WITH PRIMARY AND RECURRENT 
OROPHARYNGEAL CANDIDIASIS (n=150)
No.of patients Percentage
Primary OPC 102 68
Recurrent OPC 48 32
68% of the patients presented with primary oropharyngeal candidiasis 
and remaining 32% presented with recurrent oropharyngeal candidiasis.
TABLE-10
DISTRIBUTION OF ORAL CANDIDA ISOLATES AMONG PATIENTS 
WITH PRIMARY AND RECURRENT OROPHARYNGEAL 
CANDIDIAISIS (n=152)
SPECIES
Patients with 
Primary OPC
Patients with
Recurrent   OPC
N % N %
Candida albicans 84 55.2 34 22.3
Candida tropicalis 11 7.2 6 3.9
Candida krusei 4 2.6 4 2.6
Candida parapsilosis 2 1.3 4 2.6
Candida glabrata 2 1.3 - -
Candida guilliermondi 1 1 - -
Total 104 68.6 48 31.4
There was no statistically significant difference in species distribution 
between patients with primary and recurrent OPC.(P value = 0.281)
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TABLE -11
ANTIFUNGAL SUSCEPTIBILITY  BY DISK DIFFUSION METHOD 
(n=152)
    Susceptible
    n              %
     SDD/ I
 n           %
    Resistant
     n           %
Fluconazole 121 79.6 10 6.6 21 13.8
Itraconazole 115 75.7 13 8.6 24 15.8
Amphotericin 
B
150 100 NA NA - -
Ketaconazole 125 82.2 21 13.8 6 4
Clotrimazole 123 81 15 10 14 9
Nystatin 123 81 22 14 7 5
NA –Not applicable
By  disk  diffusion  method,  21  (13.8%)  isolates  were  resistant  to 
fluconazole,  24(15.8%)  were  resistant  to  itraconazole.  All  the  isolates  were 
susceptible to amphotericin.6(4%) were resistant to ketaconazole, 14(9%) were 
resistant to clotrimazole and 7(5%) were resistant to nystatin.
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TABLE - 12
DISTRIBUTION OF THE SUSCEPTIBITY PATTERN AMONG THE CANDIDA 
ISOLATES BY DISK DIFFUSION METHOD (n=152)
Species Totaln
Fluconazole Itraconazole Ampho-B Ketaconazole Clotrimazole Nystatin
S SDD R S SDD R S R S I R S I R S I R
C.albicans  
      
118 103 7 8 99 7 12 118 - 98 17 3 102 9 7 103 11 4
C.tropicalis 17 11 2 4 7 3 7 17 - 12 3 2 11 2 4 7 7 3
C.parapsilo 6 6 - - 5 - 1 6 - 6 - - 1 3 2 5 1 -
C.Krusei 8 - - 8 3 2 3 8 - 7 - 1 7 1 - 5 3 -
C.glabrata 2 - 1 1 - 1 1 2 - 1 1 - 2 - - 2 - -
C.guilliermo 1 1 - - 1 - - 1 - 1 - - - - 1 1 - -
Total 152 121 10 21 115 13 24 152 - 125 21 6 123 15 14 123 22 7
Percentage 100 79.6 6.61 13.8 75.7 8.5 16 100 - 82.2 14 4 81 10 9 81 14 5
TABLE-13
ANTIFUNGAL SUSCEPTIBILITY BY MICROBROTH DILUTION 
METHOD (n=152)
Susceptible SDD Resistant
N % N % N %
Fluconazole 121 79.6 13 8.6 18 11.8
Itraconazole 116 76.3 13 8.6 23 15.1
Amphotericin B 152 100 - - - -
11.8% of the Candida isolates were resistant to fluconazole and  15.1% 
were  resistant  to  itraconazole.   All  the  isolates  were  susceptible  to 
amphotericin B.
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TABLE -14
MIC OF FLUCONAZOLE BY MICRO BROTH DILUTION METHOD (n=152)
Species No of isolates
Fluconazole by broth dilution
Susceptible
<8µg/ml
SDD
16-32µg/ml
Resistant
>64µg/ml
n % n % n %
C.albicans 118 103 87.3 9 7.6 6 5.1
C.tropicalis 17 11 64.7 2 11.8 4 23.5
C.parapsilosis 6 6 100 - - - -
C.Krusei 8 - - 1 12.5 7 87.5
C.glabrata 2 - - 1 50 1 50
C.guilliermondi 1 1 100 - - - -
Total 152 121 79.6% 13 8.6 18 11.8
5.1%  of  the  Candida  albicans, 23.5%  of  the  C.tropicalis,  87.5% of  the 
C.krusei   and 50% of the C.glabrata isolates showed MIC in the resistant range  of 
>64µg/ml for fluconazole.
TABLE - 15
MIC OF ITRACONAZOLE BY MICROBROTH DILUTION METHOD (n=152)
Species No. of isolates
Susceptible
≤0.125µg/ml
SDD
0.25-5µg/ml
Resistant
≥ 1µg/ml
n % n % n %
C.albicans 118 99 83.9 7 5.9 12 10.2
C.tropicalis 17 08 47.1 3 17.6 6 35.3
C.parapsilosis 6 5 83.3 - - 1 16.7
C.krusei 8 3 37.5 2 25 3 37.5
C.glabrata 2 - - 1 50 1 50
C.guilliermondii 1 1 100 - - - -
Total 152 116 76.3 13 8.6 23 15.1
 
10.2%  of  the  Candida  albicans,  35.3%  of  the  C.tropicalis ,16.7%  of 
C.parapsilosis, 37.% of the C.krusei and 50% of the Candida glabrata showed MIC 
in the resistant range of ≥ 1µg/ml for itraconazole.
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TABLE – 16
ANTIFUNGAL SUSCEPTIBILITY OF AMPHOTERICIN –B BY 
MICROBROTH DILUTION (n=152)
Species No of isolates Susceptiblen ( %)
Resistant
>1µg/ml
C.albicans 118  118(100%)    -
C.tropicalis   17    17(100%)    -
C.parapsilosis     6    6 (100%)    -
C.Krusei     8   8 (100%)    -
C.glabrata     2   2 (100%)    -
C.guilliermondi     1   1 (100%)    -
Total 152   152(100%)
All the 150 isolates showed MIC in the susceptible  range to amphotericin.
TABLE – 17
COMPARISON OF RESISTANCE OF CANDIDA ISOLATES BY DISK 
DIFFUSION AND MICROBROTH DILUTION
Species
Fluconazole Itraconazole
Disk 
diffusion
Microbroth 
dilution
Disk
Diffusion
Microbroth
Dilution
C.albicans 8 6 12 12
C.tropicalis 4 4 7 6
C.parapsilosis - - 1 1
C.Krusei 8 7 3 3
C.glabrata 1 1 1 1
C.guilliermondi - - - -
Total 21 18 24 23
Percentage 13.8 11.8 15.8 15.1
By disk diffusion 21(13.8%) isolates were found to be fluconazole resistant 
and 24 (15.8%)isolates were found to be itraconazole resistant whereas by microbroth 
dilution 18 (11.8%) isolates were  found to be fluconazole resistant and 23 (15.1%) 
isolates were itraconazole resistant.
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TABLE - 18
DISTRIBUTION OF FLUCONAZOLE AND ITRACONAZOLE 
RESISTANCE CANDIDA ISOLATES AMONG PRIMARY AND 
RECURRENT CASES
Drug Primary Recurrent
Fluconazole  (n = 18) 7 39 % 11 61 %
Itraconazole (n = 23) 7 30.5% 16 69.5 %
61% of  the  fluconazole  resistant  isolates  were  isolated  from patients 
with recurrent candidiasis and 39% from primary cases.
About 69.5% of the itraconazole resistant isolates were isolated from 
recurrent  cases  and  30.5%  from  the  primary  case.  There  is  a  significant 
difference in itraconazole resistance between primary and recurrent cases(Chi 
square test :p value<0.001).
TABLE -19
CORRELATION OF  HIV PATIENTS WITH ORAL CANDIDIASIS 
WITH THE CD4+ T CELL COUNT (n=150)
CD4 Cells/ µl No of Patients Percent
<50 23 15.3
51-200 83 55.4
201-350 30 20
351-500 12 8
>500 2 1.3
Total 150 100
Among the 150 HIV patients with Candidiasis ,  106 (70.7%) patients 
had CD4 count < 200 Cells/µl. This was found to be statistically significant by 
proportional test(p<0.001)
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TABLE - 20
CD4 DISTRIBUTION AMONG THE CANDIDA ISOLATES (n=152)
CD4 cells /µl Candida albicans Non albicans
n=118 % n=34 %
<50 18 15.2 5 14.7
51-200 64 54.2 21 61.7
201-350 26 22 04 11.8
351-500 9 7.6 03 8.8
>500 1 01 01 2.9
Total 118 100 34 100
70.1% of the Candida albicans and 76.4% of the non albicans Candida 
sp. were isolated from the patients CD4 count <200 cells / µl.
TABLE- 21
CD4 DISTRIBUTION AMONG THE FLUCONAZOLE RESISTANT 
CANDIDA ISOLATES
CD4 cells/µl
Candida albicans(n=118) Non albicans(n=34)
No of 
Resistant 
isolates
n=6
Percentage of 
isolates 
resistant to 
fluconazole
No of 
Resistant 
isolates
n=12
Percentage of 
isolates 
resistant to 
fluconazole
<50 03 2.5 % 02 05.8 %
51-200 02 1.6 % 09 26.4 %
201-350 01 0.8 % 01 02.9 %
351-500 - - - -
>500 - - - -
Among the 34  non albicans isolates,  11 (32.2%) fluconazole resistant 
isolates were seen in patients with CD4 <200 cell/µl   and 1 (2.9%) fluconazole 
resistant isolate was seen in patients with CD4>200 cells/ µl. Among the 118 
Candida albicans isolates ,5 (4.1%) were seen in patients  CD4 <200 cells/ µl 
and 1 (2.9%) fluconazole resistant isolate was seen in patients with CD4>200 
cells/ µl.
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DISCUSSION
Oral Candidiasis is the most common fungal infection in HIV infected 
patients and has been identified as a clinical predictor for progression to AIDS.
There have been several  studies on Oral Candidiasis  in HIV infected 
patients. In the recent past, these studies shows an increasing incidence of  non-
albicans Candida spp.  in Oral Candidiasis and increasing rates of antifungal 
drug resistance particularly with the immunocompromised patients. Hence this 
study  was  done  to  speciate  and  to  determine  the  antifungal  susceptibility 
pattern of the Candida isolates from HIV patients with Oral Candidiasis and to 
correlate it with the CD4 count of the patients.
In the present study,  majority of the patients were in the age group of 
29-39 years ( 43%).(Table-1) This correlated with the study of CA Enwuru et al 
2008,  in  which  majority  of  the  patients  were  within  29-39  years  of  age 
accounting  for  42%.In  contrast  ,  in  the  study  done  by  Bandar  et  al  2006, 
majority of the patients were in the age group of 20-30 years(85%)
 There  was  a  male  preponderance  accounting  for  69% in  this  study 
(Table -2)  VP Baradkar et 2009 and Prinscilla da et al 2002, also reported 
similar results in their  studies.In contrast,  Latiff  et al 2004  showed female 
preponderance constituting 74.7% of the study group.
 In  the  present  study,  Pseudomembranous  candidiasis  was  the 
predominant type of Oral  candidiasis  seen in 93 patients(62%) followed by 
pseudomembranous and erythematous lesions  in  42  patients(28%).(Table-3). 
This was similar to the study of Hamza et al, 2008, in which 66.4% patients 
had  pseudomebranous  type  of  lesion  followed  by  22.6%  patients  with 
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pseudomembranous and erythematous type of lesion whereas Ranganathan et 
al , 2008, reported pseudomembranous as the most common type followed by 
erythematous type.
In the current study, among the 150 HIV patients with Candidiasis, 43 
(28.7%) were on HAART and majority of them were on HAART for less than 3 
months duration.107( 71.3%) were not on HAART at the time of enrollment of 
the study.In the study done by Hamza et al  2008, 36.6% were on HAART and 
the study by Princilla et al, 37% were under HAART at the time of enrollment 
of the study.
           Out of 150 samples processed, Candida was isolated from SDA culture 
in all 150 (100%) samples. Of these , two revealed a mixture of two species 
constituting for the 152 isolates.(Table-5 & 6) This correlated well with the 
study of Hamza et al 2008 and Shoba D Nadagir 2008 et al where there was 
100%  Culture  positivity  on  SDA agar.  The  study  of  Prinscilla  et  al  2002 
showed  100%  culture  positivity  with  11  patients  harboring  more  than  one 
Candida spp. 
Out  of  the  152  Candida  spp. isolates  obtained  in  the  present  study, 
species identification revealed that 118(78%) were  Candida albicans which 
was the most frequently isolated species and the remaining  34(22%) were non-
albicans Candida spp.(Table-7) This was comparable to the studies done by 
Usha arora et al 2009 , Shoba D Nadagir et al 2008 , VP Baradkar et al  2009 
where Candida albicans was the major isolate accounting for 75% , 66.6% and 
70% respectively.In his study, Latiff et al 2004, reported  86% of isolates as 
Candida albicans which was found to be slightly higher than the present study .
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In  this  study,  among  the  32  non-albicans  Candida  spp., Candida 
tropicalis was the  most common isolate seen in 17(11%) isolates followed by 
Candida krusei in 8(5%), Candida parapsilosis in 6(4%), Candida glabrata in 
2(1%) and Candida guilliermondi in 1 (1%) isolate. Candida dubliniensis was 
not  isolated in this  study.(Table-8) This  correlated with the studies  of  Usha 
Arora et al 2009, and CA Enwuru et al 2008, where Candida tropicalis was the 
most  common  non albicans  species.  In  contrast,  Bharadkar  et  al  2008 and 
Latiff et al 2004 has showed Candida parapsilosis,  as the most common non 
albicans isolate accounting for 15% and 8% respectively. Hamza et al 2008, 
and Prinscilla et al 2002, reported  Candida glabrata  as the commonest non 
albicans isolate in their studies.
In  the  present  study,  out  of  150  patients  with  oral  Candidiasis,  102 
(68%)  patients  presented  with  primary  oral  candidiasis  and  about  48(32%) 
patients presented with recurrent candidiasis. (Table-9). Majority of the patients 
with recurrent candidiasis had a history of only one previous episode of oral 
candidiasis.In  the  study  done  by  Hamza  et  al  2008,  56.2% of  the  patients 
presented with primary candidiasis and 43.8% with recurrent Candidiasis.
In this study, out of the 152 isolates, 104 (68.6%) were isolated from 
patients  with primary candidiasis  and 48(31.4%) from recurrent candidiasis. 
Species distribution of the Candida isolates among the patients with primary 
Candidiasis  reveals that , Candida albicans was the most common isolate  84 
(55%)  followed  by  Candida  tropicalis which  accounts  for  11  isolates(7%) 
.Similarly among the patients with recurrent candidiasis .Candida albicans was 
the frequent isolate 34 (22%) followed by  Candida tropicalis 6 (3.9%).There 
was  no  statistically  significant  difference  in  species  distribution  between 
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patients  with primary and recurrent Candidiasis  (P = 0.281).(Table-10) This 
correlated very well with the study done by Hamza et al 2008 where 55.7% of 
the candida isolates were isolated from patients with  primary candidiasis and 
44.3% from recurrent Candidiasis.  Candida albicans  was the most frequent 
isolate followed by Candida glabrata in both primary and recurrent candidiasis 
patients with no statistically significant difference.
Fichtenbaum et al 2000 and Cartledge et al 1999 suggests that recurrent 
infections resulted in  repeated exposure to antifungal  agents  and this  might 
predispose to a shift  to non albicans species.In the present study ,  however 
Candida albicans was the most common isolate in both primary and recurrent 
candidiasis .This could be explained by the fact that majority of the patients 
with  recurrent  candidiasis  had  only  one  previous  episode  of  oropharyngeal 
candidiasis.
The antifungal susceptibility pattern of the Candida isolates determined 
by  the  disk  diffusion  method  revealed  that  21(13.8%)  of  the  isolates  were 
fluconazole  resistant,  24(15.8%)  isolates  were  itraconazole  resistant,6(4%) 
isolates were ketaconazole resistant, 14 (9%) were clotrimazole resistant and 
7(5%) were nystatin resistant.(Table 11) 
The current study revealed that  by disk diffusion, fluconazole resistance 
was observed in 7% of the Candida albicans, 23.5% of C.tropicalis , 100% of 
C.krusei and 50% of C.glabrata.The higher incidence of resistance in C.krusei 
and  C.glabrata was  due  to  the  fact  that  they  are  intrinsically  resistant  to 
fluconazole.
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         In the present study, the antifungal susceptibility pattern determined by 
Microbroth  dilution  method  shows  that  about   18  (11.8%  )  isolates  were 
resistant to Fluconazole and 23 (15.1%) were resistant to itraconazole.All the 
isolates were susceptible to amphotericin(100%).(Table-13) This was similar to 
the  study  done  by  Usha  et  al  2009  where  11.5%  of  the  isolates  were 
fluconazole  resistant.  CA  Enwuru  et  al  2008  showed  that   fluconazole 
resistance was observed in 9.5%  of the  Candida  isolates where the resistant 
rates  were  found  to  be  slightly  lower  than  the  current  study  .The  study 
conducted by Hamza et al 2008, reveals that 5%  and 8.4% of the  Candida 
isolates were resistant to fluconazole and itraconazole respectively. Carolina et 
al 2006 reported 8.1% of the isolates were fluconazole resistant and about 8.1% 
were  resistant  to  itraconazole  and  no  resistance  to  amphotericin  B.   Many 
studies done by Bailey et al 1994, Chavanet et al 1994 have  estimated the 
incidence of clinical fluconazole resistance to be from 6 to 36%.
 In the current study, fluconazole resistance was observed in 5.1% of the 
Candida  albicans.Candida  krusei shows  87.5%  resistance  to  the 
fluconazole  .Candida  glabrata  shows  50%   and  C.tropicalis shows  23.5% 
resistance  to  fluconazole  (Table  -14).  Resistance  was  mainly  among  non 
albicans Candida spp. that are primarily / intrinsically resistant to fluconazole 
whereas in the study conducted by CA enwuru et al, fluconazole resistance by 
microbroth dilution method revealed resistance in 10% of the C.albicans , 7.7% 
of  the  C.tropicalis and  40% of  the  C.krusei.  Shoba  Nadagir  et  al  showed 
fluconazole  resistance  in  12.2%  of C.albicans which  was  higher  than  the 
resistant rate reported in this study.
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In  this  study,  itraconazole  resistance by  broth  dilution  was 10.2% in 
C.albicans, 35.3% in C.tropicalis, 16.7 % in C.parapsilosis, 50% of C.glabrata 
and  37.5%  of  C.krusei.  (Table-15)  whereas  Vargas  et  al  2005,  showed 
itraconazole resistance in 11% of C.albicans, 7% of the C.glabrata , 18.2% of 
C.tropicalis and no resitance to C.parapsilosis.
In  the  present  study  ,  there  has  been  increased  resistance  to  azoles 
particularly  among  non-albicans  isolates.  This  emphasizes  the  need  for 
speciation of the candida isolates from HIV patients with oral Candidiasis.
 Comparison of the susceptibility pattern of the isolates detected by disk 
diffusion and microbroth dilution showed minor discrepancies in the current 
study. (Table-17) Disk diffusion zone diameters were highly reproducible and 
correlated  well  with  microdilution,  making agar  based  methods  as  a  viable 
alternate to broth dilution. Disk diffusion is an easy and practical technique to 
screen antifungal agents when compared to the broth dilution which is a costly 
and cumbersome procedure. However data on agar based tests for itraconazole 
and amphotericin B are scarce, emphasizing the further research to standardize 
other antifungal agents. 
In  this  study,  among  the  itraconazole  resistant  isolates,  69.5%  were 
isolated from patients with recurrent candidiasis as compared to 30.5% from 
primary cases. 61% of the fluconazole resistant isolates were from patients with 
recurrent candidiasis and 39% from primary cases. (Table-18) The association 
between azole resistance and recurrent candidiasis was found to be statistically 
significant.(p value=0.001).This was similar to the study done by Hamza et al 
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where there  was significant  association between itraconazole  resistance  and 
recurrent candidiasis.
In the present study, among the 150 HIV patients with oropharyngeal 
candidiasis, 106  (70.7%) patients had CD4 count <200 cells /mm3    which was 
statistically  significant  by  proportional  test  (p=  <0.001)  (Table-19)  This 
correlated well with the study conducted by Usha et al where 76.66% patients 
with orophayngeal candidiasis had CD4 count <200 cells/ µl. Singh et al 2007 
also reported that there is increased risk of oropharyngeal candidiasis in HIV 
patients with progressive immunodeficiency . Therefore even when patient’s 
CD4  count  is  not  known,  presence  of  oral  lesions  of  candidiasis  may  be 
considered as a marker  of immunosuppression.
In  the  current  study  there  was  significant  association  between  non 
albicans  and fluconazole  resistance with  CD4 count  (p  value-0.004).  About 
32.2% of the fluconazole resistant, non albicans isolates were seen in patients 
with CD4 less than 200 cells/µl. (Table- 20 & 21).This correlated well with the 
study done by Usha et al 2009 indicating that the level of immunosuppression 
is an important risk factor in the emergence of resistance in yeast isolates.
SUMMARY
• In the present study, majority of the study population belonged to the 
age group of 29 – 39 years (43%).
• There was a male preponderance accounting for 69%.
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• Majority  of  the  HIV  patients  with  oropharyngeal  Candidiasis 
presented with pseudomembranous type of lesions constituting for 
62%.
• 150 samples from HIV patients with oral Candidiasis were studied in 
detail and  Candida species were isolated from all the 150 samples 
yielding a culture positivity of 100%
• Out  of  the  150  patients  ,  two  patients  showed  more  than  two 
Candida isolates resulting in a total of 152 Candida isolates.
• Majority of the isolates were Candida albicans (78%) and remaining 
were non-albicans Candida species (22%)
• Among the  non-albicans,  Candida tropicalis  (11%) was the  most 
common  isolate  followed  Candida  krusei  (5%),  Candida 
parapsilosis (4%),  C.glabrata (1%)  and  Candida  guilliermondii 
(1%).
• Among the 150 HIV patients with oropharyngeal candidiasis , 32% 
presented with recurrent Oropharyngeal Candidiasis.
• By  Disk  Diffusion  Method,  13.8%  of  the  Candida isolates  were 
resistant  to  fluconazole,  15.8% were resistant  to  itraconazole,  4% 
were  resistant  to  ketaconazole,  9% to  clotrimazole  and  5% were 
resistant to nystatin.
• By microbroth  dilution,  11.8% of  the  Candida isolates  exihibited 
MIC in the resistant range (> 64µg/ml) for fluconazole and 14 % of 
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the  isolates  exihibited  MIC  in  the  resistant  range(>1  µg/ml)  for 
itraconazole.
• Itraconazole resistant isolates were more common in patients with 
recurrent candidiasis.
• All the isolates were susceptible to amphotericin B.
• Antifungal  susceptibility  results  by  disk  diffusion  method  were 
comparable with that of microbroth dilution method.
• Out of the 150  HIV patients with oropharyngeal candidiasis, 70.6% 
had CD4 count less than 200 cells/ µl    indicating the association of 
candidiasis with immunosuppression.
• Azole  resistance  and   non  albicans  Candida  isolates  were  more 
common in HIV patients with  CD4 count <200 cells/ µl  indicating 
the  emergence  of  resistant  Candida isolates  with 
immunosuppression.
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CONCLUSION
In conclusion, Candida albicans is the most frequently isolated species 
from HIV seropositive patients  with primary as well as recurrent Candidiasis. 
Non- albicans  Candida  species  are  emerging  as  important  pathogens  with 
increasing  rates  of  azole  resistance  and with  increased  immunosuppression. 
Since  oral  candidiasis  may  be  considered  as  indirect  marker  of 
immunosuppression in HIV patients,  regular oral check up of these patients 
could be an indicator of immunosuppression. Further the increasing rates of 
resistance particularly among the  non- albicans Candida spp.  emphasizes the 
need for speciation and determination of antifungal susceptibility pattern of the 
oral candida isolates from HIV patients with oropharyngeal candidiasis.
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ABBREVIATIONS
AIDS - Acquired Immunodeficiency Syndrome
CLSI - Clinical Laboratory Standard Institute
DMSO - Dimethyl Sulfoxide
DNA - Deoxyribonucleic Acid
EDTA - Ethylene Diamine Tetraacetic acid
ELISA - Enzyme Linked Immuno Sorbent Assay
EUCAST - European Committee of Antimicrobial Susceptibility test  
FACS - Fluorescent Activated Cell Sorter
HAART - Highly Active Antiretroviral Therapy
HIV - Human Immunodeficiecy Virus
KOH - Potassium hydroxide
MHA - Mueller Hinton Agar 
MIC - Minimum Inhibitory Concentration 
MOPS - 3N-Morpholino propane sulphonic acid
NCCLS - National Committee for Clinical Laboratory standards
OPC - Oropharyngeal Candidiasis
RNA - Ribonucleic Acid
RPMI - Rosewell Park Memorial Institute
SDA - Sabourauds Dextrose Agar
SDD - Susceptible Dose Dependent
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APPENDIX
I.POTASSIUM HYDROXIDE SOLUTION(10% KOH)
Potassium hydroxide - 10 gm
Glycerol          - 10 ml
Distilled water          - 80 ml
To solution of 10% KOH, 10% glycerol is added to prevent drying. The ingredients 
are mixed and stored at room temperature.
II GRAM STAINING
Methyl Violet(2%) - 10g Methyl Violet in 100ml absolute alcohol in 1 litre of 
distilled water(Primary stain)
Grams Iodine - 10g iodine in 20g KI (fixative)
Acetone - Decolourising agent
Dilute Carbol fuchsin (1%)-      Secondary stain
III SABOURAUD DEXTROSE AGAR WITH ANTIBIOTICS
Composition:
Peptone -           10 gm
Dextrose -           40 gm
Agar -           20 gm
Distilled water -           1000ml
Chloramphenicol - 50 mg
Final pH was adjusted to 5.6
94
Media Preparation
The above ingredients were reconstituted in one litre of distilled water. Dissolve the 
powder in distilled water by boiling.Dissolve Chloramphenicol in 10ml of 95% alcohol and 
added to the boiling medium.The medium was then removed from heating , mixed well and 
then dispersed in  tubes  and autoclaved at  121  C for  15 minutes   and the final  pH was⁰  
adjusted to 5.6.The tubes were cooled in slanted position and later the slants were stored in 
refrigerator.
IV CHROM AGAR CANDIDA (Hi-CHROM Candida Differential Agar)
Ingredients     Grams/ Litre
HiVeg Special Peptone          15
Yeast Extract                              4
Dipotassium Hydrogen phosphate            1
Chromogenic mixture                                  7.22
Chloramphenicol                                          0.50
Agar                                                              15
Ph : 6.3±0.2
Suspend 42.72 grams in 1000ml of distilled water. Heat to boiling to dissolve the 
medium completely. Cool the medium to 50 C and pour into sterile petridishes.⁰
V.CORNMEAL-TWEEN 80 AGAR
Composition
Corn meal       50 gm 
Agar       15 gm
Distilled Water      1000ml 
Tween 80(1%)       3 ml                                                                               
Suspend the ingredients in 1000ml distilled water. Boil to dissolve completely. Add 
Tween80 to the above medium. 
Sterilise by autoclaving at 121 C for 15 minutes. ⁰
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VI.YEAST NITROGEN BASE AGAR MEDIUM (Dehydrated Media supplied by Hi-
Media )
Ingredients Grams/L Ingredients Grams/L
Ammonium sulphate
L-Histidine 
hydrochloride
DL-Methionine
DL-Tryptophan
Biotin
Calcium pantothenate
Folic acid
Inositol
Niacin
Para amino benzoic acid
Pyridoxine hydrochloride
Riboflavin
5.00
0.01
0.02
0.02
0.000002
0.00004
0.000002
0.02
0.0004
0.0002
0.0004
0.0002
Thiamine hydochloride
Boric acid
 Copper sulphate
 Potassium iodide
 Ferric chloride
 Manganese sulphate
 Sodium molybdate
 Zinc Sulphate
Monopotassium phosphate
Magnesium sulphate
Sodium chloride
Calcium chloride
0.004
0.0005
0.00004
0.0001
0.0002
0.0004
0.0002
0.0004
1.00
0.50
0.10
0.10
Dissolve 6.7 gms of the media in 100ml of distilled water. Sterilise by filtration and 
store at 4 C.⁰
VII CARBOHYDRATE FERMENTATION MEDIA
Peptone         - 15 gms
Sugar to be tested        -      20 gms
NaCl                                 -        5 gms
Distilled water        - 1000ml
 Dissolve  the  peptone,  Bromothymol  blue  indicator   and  sodium chloride  in  1000ml  of 
distilled water and 20 gms of the sugar to be tested. Distribute approx 5ml in sterile test 
tubes containing an inverted Durham’s tube (for gas production).Sterilise by autoclaving at 10 
pounds pressure.
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VIII MUELLER HINTON AGAR
Beef infusion - 300ml
Casein hydrolysate - 17.5 gm
Starch - 1.5 gm
Agar                           - 10gm
Distilled Water          - 1000ml
pH – 7.4
Sterilise by autoclaving at 121 C for 20 minutes.⁰
IX RPMI 1640 (ROSEWELL PARK MEMORIAL INSTITUTE ) MEDIA
RPMI medium – 10.4 gm
MOPS buffer- 34.43gm
Dissolve  powdered  medium  in  900ml  distilled  water  .Add  MOPS  to  a  final 
concentration of 0.165mol/L and stir until dissolved. While stirring, adjust the pH to 7.0 at 25 
C . Add  additional water to bring medium to a final volume of 1000ml .Filter sterilize and⁰  
store at 4 C⁰
X Mc Farland 0.5 Turbidity standard
• Prepare  this  turbidity standard  by adding  0.5ml  of  1.175% BaCl2  to  99.5ml  of 
0.H2SO4 with constant stirring to maintain a suspension.
• Verify the correct density of the turbidity standard by using a spectrophotometer.The 
absorbance at 625nm should be 0.08 to 0.10 for the 0.5 McFarland standard
• Distribute 4 to 6ml into screw capped tubes and tightly seal thse tubes and store 
them in the dark at room temperature.
• Vigorously agitate this turbidity standard on a mechanical vortex just before use.
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XI SUGAR ASSIMILATION PATTERN
Species Glucose Lactose Sucrose Raffinose Trehalose
Candida albicans   + - + -  +
Candida dubliniensis   + - + -  +
Candida glabrata   + - - -  +
Candida guilliermondii   + - + +  +
Candida kefyr   + + + +  -
Candida krusei   + - - -  -
Candida parapsilosis   + - + - +
Candida tropicalis   + - + - +
(Mackie and McCartney Practical Medical Microbiology) 
XII SUGAR FERMENTATION PATTERN
Species Glucose Lactose Sucrose Maltose
Candida albicans   + - - +
Candida dubliniensis   + - - -
Candida glabrata   + - - -
Candida guillermondii   + - + -
Candida kefyr   + + + -
Candida krusei   + - - -
Candida parapsilosis   + - - -
Candida tropicalis   + - + +
(Mackie and McCartney Practical Medical Microbiology)
98
PROFORMA
S.No:  IP/OP No.
Name of the patient  : Occupation :
Age : Marital status :
Sex                             :                          Address          :
Chief Compliants:                                 Duration
Presenting illness:
H/o Difficulty in swallowing
H/o pain and burning sensation
Past History :
H/o similar illness in the past : Yes/No
         No. of episodes
                    Treatment details
H/o past medical illness
Personal History : Smoking :                        Dietary habits:
Treatment History :
 HAART: Yes/ No
    Duration of treatment 
    Type of regimen
General Examination :
Local Examination : Oral Ulcer /patch, Site, Distribution
Laboratory Investigations :
HIV Status                                                                     CD4 count
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Mycological Investigations
Specimen – Oral Swab
Microscopy 
Gram’s Stain :
Culture on SDA 
Colony morphology
Gram stain
Culture on CHROM agar
Germ tube test
Growth on Cornmeal agar
Biochemical Reactions
Sugar Fermentation test
Glucose                                       Lactose
Sucrose                Maltose
Sugar assimilation test
Dextrose                 Sucrose
Lactose        Trehalose
Raffinose
Antifungal Susceptibility Test:
Disk Diffusion test :
Fluconazole                            Amphotericin B
 Itraconazole                            Ketaconazole
                     Clotrimazole                            Nystatin
Micro broth dilution test
Fluconazole     Itraconazole            Amphotericin B
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